CYTEK BIOSCIENCES INC
Cytek Biosciences (CTKB) develops spectral flow cytometry systems, reagents and analysis software used by research institutions, biopharma and clinical laboratories. Its instruments aim to measure many parameters per cell, supporting deeper immunophenotyping and single‑cell studies. The company’s revenue mix commonly combines one‑off instrument sales with recurring consumables and software licences, which can support steadier revenue as the installed base expands. Growth drivers include broader adoption of spectral cytometry, new product introductions and partnerships with pharmaceutical and diagnostic customers. Key risks are strong competition from established instrument makers, continued need for R&D investment, supply‑chain and manufacturing execution, and sensitivity to research spending cycles. As a small‑cap company (market capitalisation roughly $530m), CTKB may exhibit greater volatility and lower liquidity than larger peers. This summary is general educational information only and not personal advice; values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cytek's stock, believing it could rise from $3.55 to $6.
Financial Health
Cytek Biosciences is showing strong revenue and cash flow, and its profits are healthy.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
AVANTOR INC
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
Baskets Featuring CTKB
Cell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Adoption of Spectral Cytometry
Spectral cytometry can enable higher‑parameter analysis, so broader adoption could support long‑term growth — though customer uptake and competition will influence outcomes.
Recurring Consumables Revenue
Consumables and software licences offer recurring revenue potential that can stabilise sales beyond instrument purchases, yet revenue can vary with research budgets.
Market & Competition
The addressable market spans academic, clinical and pharma customers, but Cytek faces established players and execution challenges; investors should watch commercial traction closely.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.